Kashyap Tele-Medicines Ltd

Kashyap TeleMed's historical performance shows stable net sales and operating income at 0.19 Cr for the last two years, with reduced total expenditure indicating cost management. However, profitability remains a challenge, with negative earnings per share and fluctuating operating profits, resulting in no profit before or after tax in recent years.

Kashyap TeleMed will announce its results on 12 November 2025.

As of the latest data, Kashyap TeleMed's stock price has risen by 7.98% over the past week, with a year-to-date increase of 228.87% and a 413.19% rise over the past year, indicating strong investor confidence despite a declining broader market. The stock's performance significantly outpaces the Sensex, which has dropped by 1.05% in the same period.

Kashyap TeleMed has shown low net sales and fluctuating profitability, with stable net sales of 0.19 Cr in recent years and a history of operating losses, including a significant loss of 1.73 Cr in Mar'22. The company faces challenges in achieving profitability and operational efficiency.

Kashyap TeleMed will announce its results on 14 August 2025.

As of 24th July, Kashyap Tele-Medicines Ltd has a market capitalization of 38.00 Cr, classifying it as a Micro Cap company, with recent net sales of 0.20 Cr and a net loss of 0.01 Cr over the latest four quarters. Data for shareholder's funds and total assets is unavailable.

The top shareholders of Kashyap TeleMed are Jindal Worldwide Limited with 31.25%, Amitara Industries Private Limited with 19.01%, and individual investors holding 30.92%. There are no pledged promoter holdings, and the company is not held by mutual funds or foreign institutional investors.

As of March 2022, the management team of Kashyap TeleMed includes Amit Agrawal (Managing Director), Surabhi Agrawal, Amrita Khetan, Devkinandan Sharma, Raghav Agrawal, Mayank Khetan (all Directors), and Paritosh Trivedi (Company Secretary & Compliance Officer). Each member contributes to the company's governance and strategic direction.

Kashyap TeleMed.'s peers include Saven Tech., Titan Intech, Rolta India, Accedere, Infonative Solutions, Tridhya Tech, Yudiz Solutions, Micropro Software, and Mindpool Tech. Their management risks vary from excellent to below average, with Kashyap TeleMed. showing a significantly higher 1-year return of 177.82% compared to its peers.

As of December 27, 2024, Kashyap TeleMed's technical trend is bullish, supported by positive MACD and moving averages, although caution is advised due to a bearish monthly RSI signal.

As of December 27, 2024, Kashyap TeleMed's technical trend is bullish, supported by positive MACD and moving averages, although caution is advised due to a bearish monthly RSI signal.

Kashyap Tele-Medicines Ltd, a Micro Cap company in the Computers - Software & Consulting industry, reported net sales and net profit of 0 Cr for the quarter ending March 2025. The company, formerly known as Jindal Online.Com Limited, was incorporated in 1995.

As of 05-Jun, Kashyap Tele-Medicines Ltd's stock price is declining at 8.54, down 1.95%, and has fallen for six consecutive days, totaling an 11.13% drop. Despite strong long-term returns, recent performance shows a significant decrease in investor interest and underperformance compared to the broader market.